The lyme disease vaccine-A public health perspective

  • A.K. S
  • P.S. M
  • Shen A
 et al. 
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Lyme disease, which is caused by the spirochetal agent Borrelia burgdoferi, is the most common vector-borne illness in the United States. In 1998, the US Food and Drug Administration approved a recombinant Lyme disease vaccine that was later voluntarily withdrawn from the market by the manufacturer. Current Lyme disease prevention efforts focus on a combination of methods and approaches, including area acaricides, landscape management, host-targeted interventions, management of deer populations, and personal protective measures, such as the use of insect repellant and tick checks. Although these methods are generally safe and relatively inexpensive, the primary limitations of these methods are that their effectiveness has been difficult to demonstrate conclusively and that rates of compliance are generally poor. An effective human Lyme disease vaccine that has been adequately evaluated in the highest-risk population groups could be very beneficial in preventing Lyme disease; however, it would need to meet high standards regarding safety, efficacy, cost, and public acceptance.

Author-supplied keywords

  • *Lyme Disease Vaccines/im [Immunology]
  • *Lyme Disease Vaccines/tu [Therapeutic Use]
  • *Lyme Disease/im [Immunology]
  • *Lyme Disease/pc [Prevention & Control]
  • *Lyme disease vaccine/ae [Adverse Drug Reaction]
  • *Lyme disease vaccine/dt [Drug Therapy] XT - arth
  • *Lyme disease/dt [Drug Therapy]
  • *Lyme disease/pc [Prevention]
  • Animals
  • Arachnid Vectors/mi [Microbiology]
  • Borrelia burgdorferi
  • Borrelia burgdorferi/im [Immunology]
  • Clinical Trials
  • Humans
  • Lyme Disease/ep [Epidemiology]
  • Lyme Disease/tm [Transmission]
  • Lyme disease/dt [Drug Therapy]
  • Phase III as Topic
  • Public Health
  • Risk Factors
  • Ticks/mi [Microbiology]
  • United States/ep [Epidemiology]
  • acaricide/dt [Drug Therapy]
  • arthralgia/si [Side Effect]
  • article
  • asthenia/si [Side Effect]
  • clothing
  • cost effectiveness analysis
  • disease severity
  • drug efficacy
  • drug hypersensitivity/si [Side Effect]
  • drug mechanism
  • drug safety
  • fever/si [Side Effect]
  • flu like syndrome/si [Side Effect]
  • geographic distribution
  • headache/si [Side Effect]
  • human
  • injection site hypersensitivity/si [Side Effect]
  • injection site pain/si [Side Effect]
  • insect repellent/dt [Drug Therapy]
  • land use
  • molecular genetics
  • myalgia/si [Side Effect]
  • nonhuman
  • pain/si [Side Effect]
  • phase 3 clinical trial (topic)
  • priority journal
  • public health service
  • rash/si [Side Effect]

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Authors

  • Shen A.K.

  • Mead P.S.

  • Angela K Shen

  • Paul S Mead

  • Charles B Beard

  • Shen A.K.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free